Advertisement


Howard Jack West, MD, on New Kinase Targets for Treating Advanced NSCLC

2015 IASLC World Conference on Lung Cancer

Advertisement

Howard Jack West, MD, of the Swedish Cancer Institute, summarizes three important papers: anlotinib as third-line treatment for refractory advanced non–small cell lung cancer; the EGFR exon 20 mutation as a prognostic/predictive biomarker; and EGFR exon 18 mutations as molecular predictors of sensitivity to afatinib or neratinib (Abstracts ORAL 3.01, 3.02, and 3.03).



Related Videos

Lung Cancer

Pasi A. Jänne, MD, PhD, on Integration of Next Generation Data Into the Clinic

Pasi A. Jänne, MD, PhD, of Dana-Farber Cancer Institute, summarizes a workshop he conducted on the state of the art in next-generation sequencing of lung cancer (Abstract WS 01.07).

Lung Cancer

Tony Mok, MD, and Fred R. Hirsch, MD, PhD: Summary of the IASLC Presidential Symposium

Tony Mok, MD, of The Chinese University of Hong Kong, and Fred R. Hirsch, MD, PhD, of University of Colorado Health Science Center discuss the highlights of the featured plenary session, which included the conference’s top four abstracts (Abstract PLEN04).

Lung Cancer

William D. Travis, MD, on Pathology and Genetics of Lung Tumors: 2015 WHO Classification

William D. Travis, MD, of Memorial Sloan Kettering Cancer Center, gives an update on the WHO classification, which is crucial for optimal personalized treatment of lung cancer patients (Abstract PLEN02.01).

Lung Cancer

Heather A. Wakelee, MD, on Results of the E1505 Clinical Trial

Heather A. Wakelee, MD, of Stanford University discusses the study that explored the question of whether adding bevacizumab to adjuvant chemotherapy is beneficial in the setting of resected non–small cell lung cancer (Abstract PLEN04.03).

Lung Cancer

James L. Mulshine, MD, on Lung Cancer Screening in the United States: Can It Happen?

James L. Mulshine, MD, of Rush University Medical Center, discusses the profound challenges of implementing national CT screening to ensure delivery of high-quality, best-practice early lung cancer detection in the target population of tobacco-exposed individuals (Abstract MS 15.01).

Advertisement

Advertisement




Advertisement